MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

25.83 3.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.92

Max

26.22

Põhinäitajad
By Trading Economics
Sissetulek	258M 216M
Müük	280M 459M
P/E Sektori keskmine	69.917 88.032
Aktsiakasum	1.67
Kasumimarginaal	47.04
Töötajad	705
EBITDA	258M 228M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+68.11% upside

Turustatistika
By TradingEconomics
Turukapital	-576M 3.2B
Eelmine avamishind	22.63
Eelmine sulgemishind	25.83

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. jaan 2026, 21:07 UTC

Tulu

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2. jaan 2026, 20:09 UTC

Market Talk

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2. jaan 2026, 19:48 UTC

Market Talk

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2. jaan 2026, 18:53 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. jaan 2026, 18:53 UTC

Market Talk

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2. jaan 2026, 17:56 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2. jaan 2026, 17:50 UTC

Market Talk

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. jaan 2026, 16:33 UTC

Market Talk

Remittances to Mexico Fell 5.7% in November -- Market Talk

2. jaan 2026, 16:18 UTC

Market Talk

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2. jaan 2026, 15:48 UTC

Tulu

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2. jaan 2026, 15:17 UTC

Market Talk

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2. jaan 2026, 15:01 UTC

Market Talk

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2. jaan 2026, 15:00 UTC

Tulu

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2. jaan 2026, 14:56 UTC

Market Talk

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2. jaan 2026, 14:20 UTC

Market Talk

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2. jaan 2026, 14:20 UTC

Market Talk

Global Equities Roundup: Market Talk

2. jaan 2026, 14:13 UTC

Market Talk

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2. jaan 2026, 13:39 UTC

Market Talk

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2. jaan 2026, 13:01 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2. jaan 2026, 12:45 UTC

Market Talk

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2. jaan 2026, 11:48 UTC

Market Talk

European Gas Climbs as Cold Weather Bites -- Market Talk

2. jaan 2026, 11:36 UTC

Market Talk

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2. jaan 2026, 11:30 UTC

Market Talk

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2. jaan 2026, 11:29 UTC

Market Talk

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2. jaan 2026, 11:15 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

68.11% tõus

12 kuu keskmine prognoos

Keskmine 42.23 USD 68.11%

Kõrge 117.8 USD

Madal 22 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.